An Exceedingly Rare Case of Liraglutide-Induced Liver Injury
Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric O. Then, Tyler Grantham, Vinaya V. Gaduputi
Abstract
Open-access reader
Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric O. Then, Tyler Grantham, Vinaya V. Gaduputi
Abstract
Open-access reader
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.
OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of the drug.
Key concepts: Liraglutide, Medicine, Discontinuation, Liver injury, Agonist, Diabetes mellitus, Type 2 Diabetes Mellitus, Glucagon-like peptide 1 receptor